John Shortmoor, independent pharmaceutical companies analyst at Datamonitor, comments:
“This is a great deal for Sanofi, paying close to their original budget of $20 billion, with extra contingency payments only coming if Genzyme's multiple sclerosis drug Lemtrada exceeds Sanofi's expectations.
“Through the acquisition, Sanofi has succesfully gained access to niche markets where competition is limited by more than just patent protection - a stated aim of the company's CEO, Christopher Viehbacher - providing a platform for long-term sales growth, diversifying away from the traditional blockbuster model
“Moreover, through its strong global presence, Sanofi is in a good position to extend the geographic reach of Genzyme's portfolio, especially in growth markets, bolstering the company's long-term sales potential”
To arrange an interview or for further details regarding this release please contact Joe Dixonin the Datamonitor press office on + 44 (0)161 238 4083, or email jdixon@datamonitor.com
ABOUT DATAMONITOR
The Datamonitor Group (www.datamonitor.com) is a world-leading provider of premium global business information, delivering independent data, analysis and opinion across the Automotive, Consumer Markets, Energy & Utilities, Financial Services, Logistics & Express, Pharmaceutical & Healthcare, Retail, Sourcing, Technology and Telecoms industries. Combining our industry knowledge and experience, we assist more than 6,000 of the world’s leading companies in making better strategic and operational decisions.
